Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15197105 | 0.83 | CSNK2A1 (0.33) | CSNK2A1RORCTLR8 | |
| SCHEMBL2794945 | 0.82 | ALDH1A1 (0.38) | TSHRHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL17366270 | 0.81 | MCHR1 (0.39) | TSHRHTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL13584342 | 0.79 | MCHR1 (0.38) | MCHR1 | |
| SCHEMBL8280908 | 0.78 | FFAR4 (0.43) | TSHRHTR2AHTR2CHTR2BCSNK2A1 | |
| SCHEMBL8274298 | 0.78 | RORC (0.43) | TSHRHTR2AHTR2CHTR2BCYP1A2 | |
| SCHEMBL3537431 | 0.78 | RORC (0.43) | TSHRHTR2AHTR2CHTR2BCYP1A2 | |
| SCHEMBL24460269 | 0.78 | SLC6A4 (0.49) | CSNK2A1MAPTRORC | |
| SCHEMBL2851014 | 0.78 | ALOX15 (0.37) | CSNK2A1CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL4152456 | 0.78 | PDE4B (0.42) | CSNK2A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315492-B2 | Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof | BEIJING FORELAND BIOPHARMA CO., LTD. (CN) | 2016-04-19 | — | — | US | disclosed |
| US-9315492-B2 | Heterocyclic group contained amino-methanol derivative, and salt, synthetic method and use thereof | BEIJING FORELAND BIOPHARMA CO., LTD. (CN) | 2016-04-19 | — | — | US | disclosed |
| EP-2588451-B1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-9079864-B2 | Modulators of S1P receptors | ALLERGAN, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2015092634-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR ANTAGONISTS AND DEGRADERS | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092634-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR ANTAGONISTS AND DEGRADERS | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20150094337-A1 | HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF | BEIJING FORELAND BIOPHARMA CO., LTD. (CN) | 2015-04-02 | — | — | US | disclosed |
| US-20150094337-A1 | HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF | BEIJING FORELAND BIOPHARMA CO., LTD. (CN) | 2015-04-02 | — | — | US | disclosed |
| EP-2643303-A1 | MODULATORS OF S1P RECEPTORS | Allergan, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071186-A1 | MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129906-A1 | MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094337-A1 | HETEROCYCLIC GROUP CONTAINED AMINO-METHANOL DERIVATIVE, AND SALT, SYNTHETIC METHOD AND USE THEREOF | SSB, HLA-DRB1, MYD88 | TSHR 2212/4885HTR2A 2951/4885HTR2C 2186/4885 |
| US-20120129906-A1 | MODULATORS OF S1P RECEPTORS | S1PR1, S1PR3, S1PR2 | TSHR 353/4885HTR2A 263/4885HTR2C 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.